Survival analysis of patients with metastatic osteosarcoma: a Surveillance, Epidemiology, and End Results population-based study
- 101 Downloads
The present study is aimed at investigating whether (1) primary tumour surgery confers an improved survival on patients with metastatic osteosarcoma and (2) primary tumour surgery influences survival of patients with metastatic osteosarcoma differently according to primary tumour site.
We retrospectively identified 517 patients with high-grade, metastatic osteosarcoma in the Surveillance, Epidemiology, and End Results (SEER) database between 1994 and 2013. The effect of primary tumour surgery on survival was assessed using Kaplan-Meier analyses, log-rank tests, and multivariate Cox proportional hazard regression modeling.
Of those 517 patients with metastatic osteosarcoma in the cohort, 351 patients (68%) underwent primary surgery, and 166 patients (32%) did not undergo surgery. Primary tumour surgery was associated with increased overall survival (hazard ratio (HR) = 0.457, 95% CI 0.354–0.590, p < 0.001) and cancer-specific survival (HR = 0.422, 95% CI 0.325–0.550, p < 0.001). When we focused on different primary tumour sites, receipt of primary tumour surgery significantly prolonged the survival of patients with extremity osteosarcoma (p < 0.05 for overall and cancer-specific survival). However, for patients with pelvis/spine osteosarcoma, both univariate and multivariate analyses indicated that primary tumour surgery might not be associated with improved survival (p > 0.05 for overall and cancer-specific survival).
Our study is the first population-based analysis to provide evidence of a favourable prognostic impact of primary tumour surgery on metastatic extremity osteosarcoma patients but not metastatic axial (pelvis/spine) osteosarcoma patients. Moreover, we found that surgery type (resection of the primary tumor without amputation vs. amputation) did not influence survival in patients with metastatic osteosarcoma.
KeywordsOsteosarcoma Metastatic Surgery Survival
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Because we obtain data from the SEER database with open access, we did not need to acquire patient consent or an ethical review committee statement, but we were required to sign a Data Use Agreement for the SEER 1973–2014 Research Data File to gain access to the SEER database.
- 6.Bacci G, Briccoli A, Rocca M, Ferrari S, Donati D, Longhi A (2003) Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann Oncol 14:1126–1134CrossRefGoogle Scholar
- 10.National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Available at: http://seer.cancer.gov. Accessed 24 May 2018
- 12.Song K, Song J, Shi X, Wang H, Ma X, Xia X, Liang X, Lin K, Jiang J (2018) Development and validation of nomograms predicting overall and cancer-specific survival of spinal chondrosarcoma patients. Spine (Phila Pa 1976). https://doi.org/10.1097/BRS.0000000000002688
- 14.San-Julian M, Diaz-de-Rada P, Noain E, Sierrasesumaga L (2003) Bone metastases from osteosarcoma. Int Orthop 27:117–120Google Scholar
- 16.Biermann JS, Chow W, Reed DR, Reed DR, Lucas D, Adkins DR, Agulnik M, Benjamin RS, Brigman B, Budd GT, Curry WT, Didwania A, Fabbri N, Hornicek FJ, Kuechle JB, Lindskog D, Mayerson J, McGarry SV, Million L, Morris CD, Movva S, Randall RL, Rose P, Santana VM, Satcher RL, Schwartz H, Siegel HJ, Thornton K, Villalobos V, Bergman MA, Scavone JL (2017) NCCN guidelines insights: bone cancer, version 2.2017. J Natl Compr Cancer Netw 15:155–167CrossRefGoogle Scholar
- 17.Goorin AM, Schwartzentruber DJ, Devidas M, Gebhardt MC, Ayala AG, Harris MB, Helman LJ, Grier HE, Link MP (2003) Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol 21(8):1574–1580CrossRefGoogle Scholar
- 18.Bacci G, Rocca M, Salone M, Balladelli A, Ferrari S, Palmerini E, Forni C, Briccoli A (2008) High grade osteosarcoma of the extremities with lung metastases at presentation: treatment with neoadjuvant chemotherapy and simultaneous resection of primary and metastatic lesions. J Surg Oncol 98(6):415–420CrossRefGoogle Scholar
- 20.Nataraj V, Rastogi S, Khan SA, Sharma MC, Agarwala S, Vishnubhatla S, Bakhshi S (2016) Prognosticating metastatic osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate and delayed metastasectomy: a single center experience of 102 patients. Clin Transl Oncol 18(9):937–944CrossRefGoogle Scholar